These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Involvement of SNARE Protein Interaction for Non-classical Release of DAMPs/Alarmins Proteins, Prothymosin Alpha and S100A13. Matsunaga H; Halder SK; Ueda H Cell Mol Neurobiol; 2021 Nov; 41(8):1817-1828. PubMed ID: 32856232 [TBL] [Abstract][Full Text] [Related]
9. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. Ueda H Pain Manag; 2020 Jan; 10(1):43-53. PubMed ID: 31852400 [TBL] [Abstract][Full Text] [Related]
10. Prothymosin alpha plays a key role in cell death mode-switch, a new concept for neuroprotective mechanisms in stroke. Ueda H Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):315-23. PubMed ID: 18176798 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotective DAMPs member prothymosin alpha has additional beneficial actions against cerebral ischemia-induced vascular damages. Maeda S; Sasaki K; Halder SK; Fujita W; Ueda H J Pharmacol Sci; 2016 Sep; 132(1):100-104. PubMed ID: 27543170 [TBL] [Abstract][Full Text] [Related]
12. Systems Pathology of Neuropathic Pain and Fibromyalgia. Ueda H Biol Pharm Bull; 2019; 42(11):1773-1782. PubMed ID: 31685762 [TBL] [Abstract][Full Text] [Related]
13. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. Ma L; Matsumoto M; Xie W; Inoue M; Ueda H J Neurochem; 2009 Apr; 109(2):603-10. PubMed ID: 19222705 [TBL] [Abstract][Full Text] [Related]
14. Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Ueda H Pharmacol Ther; 2009 Sep; 123(3):323-33. PubMed ID: 19500618 [TBL] [Abstract][Full Text] [Related]